All monetary figures listed in Canadian Dollars. VANCOUVER, British Columbia, May 23, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce the undertaking of a non-brokered Private Placement (the “Offering”) for gross proceeds of up to $1.5 million at a purchase price of $0.10 per Unit.

所有货币数字均以加元列示。不列颠哥伦比亚省温哥华，2024年5月23日（环球通讯社）--Rakovina Therapeutics Inc.（TSX-V:RKV，“公司”或“Rakovina Therapeutics”）是一家致力于推进基于新型DNA损伤反应技术的新型癌症治疗的生物制药公司，很高兴宣布进行非经纪私募（“发行”），总收益高达150万美元，购买价格为每单位0.10美元。

This includes lead orders totalling approximately $1.25 million from two new investors. Each Unit will be comprised of one (1) common share of Rakovina Therapeutics common share stock and one (1) share purchase warrant at a purchase price of $0.20 for a period of three years (36 months) after the closing date of the Offering.

其中包括来自两位新投资者的总计约125万美元的潜在客户订单。每个单位将由一（1）股Rakovina Therapeutics普通股和一（1）股认股权证组成，购买价格为0.20美元，在发售截止日期后的三年（36个月）内。

If the closing price for the Common Shares on the TSX Venture Exchange (the “TSXV”) is $0.25 or greater for five consecutive trading days, the expiry date of the Warrant shall be accelerated to the date that is 30 days following the last day of the five-trading day period. The Company plans to use the proceeds primarily to support research and development activities related to its recently announced Artificial Intelligence (AI) collaboration that provides exclusive access to the proprietary Deep Docking platform for DNA-damage response targets.

如果TSX风险交易所（“TSXV”）的普通股连续五个交易日的收盘价为0.25美元或更高，则认股权证的到期日应提前至五个交易日最后一天之后的30天。该公司计划将收益主要用于支持与其最近宣布的人工智能（AI）合作相关的研发活动，该合作为DNA损伤反应目标提供专有深度对接平台的独家访问。

Over the next 12 to 16 weeks, Rakovina Therapeutics aims to screen over five billion potential drug candidates using this platform. The most promising lead candidates will be further validated in the Company's laboratories at the University of British Columbia. Rakovina Therapeutics intends to advance these validated drug candidates to clinical trials in collaboration with pharmaceutical partners.

在接下来的12至16周内，Rakovina Therapeutics旨在使用该平台筛选超过50亿种潜在候选药物。最有希望的候选药物将在该公司位于不列颠哥伦比亚大学的实验室进一步验证。Rakovina Therapeutics打算与制药合作伙伴合作，将这些经过验证的候选药物推进临床试验。

The Units will be sold on a non-b.

这些单位将以非b价出售。